Innate Pharma to present results from a preliminary analysis of the TELLOMAK Phase 2 trial in patients with advanced Sezary syndrome and ANKET platform at ASH 2022

  • Innate will share preliminary results of the cohort evaluating lacutamab in Sezary syndrome patients post-mogamulizumab from the ongoing TELLOMAK Phase 2 trial 

  • Chief Scientific Officer, Eric Vivier, DVM, PhD, to give an oral presentation on multispecific antibodies platform: ANKETTM 

  • Partner Sanofi will display two posters on SAR’579/IPH6101 and SAR’514/IPH6401

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the 64th ASH (American Society Hematology) Annual Meeting taking place from December 10-13, 2022, in New Orleans, Louisiana. 

  • Lacutamab in patients with advanced Sezary syndrome: results from an interim analysis of the TELLOMAK phase 2 trial
    • Abstract Number: 1631
    • Session Name: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I
    • Session Date and Time: Saturday, December 10, 2022, 5:30 PM - 7:30 PM
    • Location: Ernest N. Morial Convention Center, Hall D
    • Presenter: Dr Pierluigi Porcu, Director, Division of Medical Oncology and Hematopoietic Stem Cell Transplantation, Thomas Jefferson University Hospitals, Philadelphia
  • Scientific Symposia: Antibody-Based NK Cell Engager Therapeutics 
    • Session Title: Biology and Translation of NK Cells  
    • Session date and Time:  Saturday December 10th, 2022, 2:00 PM - 3:15 PM
    • Location: Ernest N. Morial Convention Center, 293-294 
    • Presenter: Eric Vivier, DVM, PhD, Chief Scientific Officer of Innate Pharma
  • An open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplasia (HR-MDS) (Sanofi)
    • Abstract Number: 3329
    • Session Name: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
    • Session Date and Time: Sunday, December 11, 2022, 6:00 PM - 8:00 PM
    • Location: Ernest N. Morial Convention Center, Hall D
    • Presenter: Anthony Stein, MD
  • The Novel Trifunctional Anti-BCMA NK Cell Engager SAR’514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement (Sanofi)
    • Abstract Number: 4486
    • Session Name: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III
    • Session Date and Time: Monday, December 12, 2022, 6:00 PM - 8:00 PM
    • Location: Ernest N. Morial Convention Center, Hall D
    • Presenter: Alexandre Tang, Ph.D

The posters and presentation will be available on the Publications section of following the meeting.

About Lacutamab:

Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, Sézary syndrome. It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues.

Lacutamab is granted European Medicines Agency (EMA) PRIME designation and US Food and Drug Administration (FDA) granted Fast Track designation for the treatment of patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies. 


ANKETTM (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.

This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer.  It leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells.

Our latest innovation, the tetra-specific ANKET molecule, is the first NK cell engager technology to engage activating receptors (NKp46 and CD16), a tumor antigen and an interleukin-2 receptor (via an IL-2 variant, IL-2v) via a single molecule.